Heat-Killed BCG as a Safe Innate Immunomodulatory Strategy for Severe Combined Immunodeficiency (SCID): Harnessing Trained Immunity Without Infectious Risk

Background: Live BCG vaccination is absolutely contraindicated in Severe Combined Immunodeficiency (SCID) due to the invariably fatal risk of disseminated BCGosis [5,6,7]. This creates a critical unmet need: SCID neonates are deprived of BCG's potent heterologous protection precisely when they are most vulnerable to opportunistic infections. Hypothesis: Heat-Killed BCG (HK-BCG), being entirely non-viable, cannot cause BCGosis or systemic mycobacterial disease. We propose that HK-BCG retains sufficient structural pattern-associated molecular patterns (PAMPs) to engage functional innate immune cells — specifically monocytes, macrophages, and NK cells — that remain present in the majority of SCID subtypes, thereby inducing trained immunity and heterologous protection without adaptive immune cell dependency [2,3,4]. Methods/Evidence: This paper synthesizes molecular mechanism data on TLR2/TLR4/NOD2-driven trained immunity [23,24], epigenetic reprogramming pathways [2,3], SCID immunophenotype data [32,33], and available non-viable mycobacterial clinical trial evidence [34] to construct a mechanistic and clinical rationale for HK-BCG use in SCID. Conclusions: HK-BCG represents a paradigm-shifting, potentially life-saving immunomodulatory platform for SCID patients. The complete absence of viable bacilli eliminates all infectious risk, while preserved mycobacterial PAMPs can train the residual innate immune compartment. This approach is particularly compelling in the post-HSCT reconstitution window. A dedicated Phase I/IIa clinical trial in SCID is urgently warranted.